Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 19.00 GBp
Change Today +2.50 / 15.15%
Volume 297.7K
As of 11:54 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

omega diagnostics group plc (ODX) Snapshot

Open
16.75 GBp
Previous Close
16.50 GBp
Day High
19.00 GBp
Day Low
16.75 GBp
52 Week High
04/28/14 - 29.00 GBp
52 Week Low
04/8/15 - 12.63 GBp
Market Cap
20.7M
Average Volume 10 Days
358.6K
EPS TTM
0.0058 GBp
Shares Outstanding
108.7M
EX-Date
--
P/E TM
32.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for OMEGA DIAGNOSTICS GROUP PLC (ODX)

Related News

No related news articles were found.

omega diagnostics group plc (ODX) Related Businessweek News

No Related Businessweek News Found

omega diagnostics group plc (ODX) Details

Omega Diagnostics Group PLC, together with its subsidiaries, manufactures, develops, and distributes medical diagnostics products. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Diseases. The Allergy and Autoimmune segment researches, develops, produces, and markets in vitro allergy and autoimmune tests that are used by doctors to diagnose patients with allergies and autoimmune diseases. This segment’s principal products include Allergozyme, Allergodip, and Genesis Elisa. The Food Intolerance segment engages in the research, development, and production of kits to aid the detection of immune reactions to food. This segment also provides clinical analysis to the general public, clinics, and health professionals, as well as supplies consumer food detective test products. Its principal products include Genarrayt microarray, Food Detective, and Foodprint service. The Infectious Diseases segment is involved in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases. Its principal products comprise Immutrep Syphilis, Micropath Bacterial tests, and Dengue Elisa. The company offers its products to hospitals, blood banks, clinics, and laboratories through distributors and sales teams in approximately 100 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.

135 Employees
Last Reported Date: 07/11/14
Founded in 1987

omega diagnostics group plc (ODX) Top Compensated Officers

Founder, Chief Executive Officer, Managing Di...
Total Annual Compensation: 145.0K GBP
Group Finance Director, Company Secretary and...
Total Annual Compensation: 115.0K GBP
Group Sales & Marketing Director and Executiv...
Total Annual Compensation: 110.0K GBP
Compensation as of Fiscal Year 2014.

omega diagnostics group plc (ODX) Key Developments

Omega Diagnostics Group PLC Appoints Colin King as Chief Operating Officer, with Effect from August 3, 2015

Omega Diagnostics Group PLC announced that Colin King has agreed to join the board as Chief Operating Officer and will take up his appointment with effect from August 3, 2015. Mr. King has over 20 years' experience in the in-vitro diagnostics industry and is currently the Managing Director of Axis-Shield Diagnostics, having joined in 1995 and held a number of positions encompassing project management, operations, planning and supply chain logistics.

Omega Diagnostics Group PLC Provides Earnings Guidance for the Year Ended March 31, 2015

Omega Diagnostics Group PLC provided earnings guidance for the year ended March 31, 2015. The company announced that results for the year to March 31, 2015 will be in line with market expectations. Revenues for the year are expected to be £12.1 million and adjusted profit before tax (before acquisition costs, share based payments, IFRS-related discount unwinds and amortisation of intangible assets) will be significantly higher than that achieved in the prior year and is expected to be approximately £1.4 million.

Omega Diagnostics Group PLC Reports Unaudited Consolidated Earnings Results for the Six Months Ended September 30, 2014

Omega Diagnostics Group PLC reported unaudited consolidated earnings results for the six months ended September 30, 2014. Revenue was £5.7 million against £5.6 million last year. Operating profit was £0.2 million against £0.2 million last year. Profit before taxation was £0.2 million against £0.2 million last year. Profit for the period was £0.2 million against £0.2 million last year. Basic and diluted EPS was 0.2 pence against 0.3 pence last year. Adjusted profit before taxation was £0.6 million against £0.4 million last year. Adjusted basic and diluted EPS was 0.5 pence against 0.6 pence last year. Net cash flow from operating activities was £0.3 million against £0.4 million last year. Purchase of property, plant and equipment was £0.4 million against £0.3 million last year. Purchase of intangible assets was £0.6 million against £0.6 million last year. Adjusted profit attributable to equity holders of the group was £0.5 million against £0.5 million last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ODX:LN 19.00 GBp +2.50

ODX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ODX.
View Industry Companies
 

Industry Analysis

ODX

Industry Average

Valuation ODX Industry Range
Price/Earnings 28.2x
Price/Sales 1.4x
Price/Book 0.9x
Price/Cash Flow 26.9x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEGA DIAGNOSTICS GROUP PLC, please visit www.omegadiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.